Cavion LLC

In an illustration of Jazz Pharmaceuticals plc ’s focus on central nervous system disorders, the company recently presented 13 posters and oral presentations at the American Academy of Neurology annu

Jazz Pharmaceuticals plc ’s mid-stage asset suvecaltamide (JZP385) failed to show a statistically significant benefit in a Phase IIb trial in patients with essential tremor, but a second Phase II stud

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions. Aevi Obtains Option For AstraZ

With a second product-orientated deal in two months, Jazz Pharmaceuticals PLC is building up a pipeline of potential specialty medicines by targeting niche investigational candidates, particularly i